Weekly Roundup: Commercial expansion, collaborations & clinical progress

Despite the short Bank Holiday week, it’s as busy as ever. Collaborative expansion is in full swing as Bonito Biosciences and Dalton^Tx join forces, and ViCentra triples Kaleido consumables production capacity through Phillips Medisize partnership. Hansa Biopharma, Poolbeg Pharma and Synklino have been enjoying progress this week, as Hansa reports positive efficacy and safety results for Idefirix, Poolbeg affirms a positive outcome to a pre-IND meeting with the FDA and Synklino announces that the first patient has been dosed in the SYN002 Phase 1 trial.

Congratulations to Renée Aguiar-Lucander, CEO at Hansa Biopharma as she was this week named one of Sweden’s Most Influential Business Women of 2026 by Dagens Industri! This fantastic recognition is testament to Renée’s individual leadership, and the role that Hansa plays in driving growth, innovation, and competitiveness.

Hansa Biopharma reported positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Hansa Biopharma AB, announced positive topline results from the European 20-HMedIdeS-19 Post Authorization Efficacy Study (PAES), an open-label confirmatory study investigating one-year graft failure-free survival and patient survival in highly sensitized patients who have undergone HLA-incompatible kidney transplantation following desensitization treatment with Idefirix (imlifidase).

Hansa also announced that results from its US Phase 3 ConfIdeS trial in kidney transplantation have been accepted and selected as a late-breaking abstract for an oral presentation at the upcoming American Transplant Congress (ATC) in Boston, June 22, 2026.

Dalton^Tx and Bonito Biosciences announce AI-driven collaboration to advance precision delivery for oligotherapeutics

Dalton^Tx, the intelligence backbone for modern drug discovery: connecting AI, human expertise and experimental data, and Bonito Biosciences, a biotechnology company building the data foundation for programmable oligotherapeutic delivery,  announced their collaboration to combine Bonito’s proprietary functional delivery data engine and ligand discovery platform with Dalton^Tx’s adaptive AI technology, accelerating precision oligotherapeutic delivery, beginning in the CNS.

Resolution Therapeutics congratulated University of Edinburgh on positive 4-year MATCH trial data on RMT in liver cirrhosis

Resolution Therapeutics Limited, a clinical-stage biopharmaceutical company pioneering engineered Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, welcomed on Monday the publication of positive four-year follow-up data from the University of Edinburgh’s MATCH trial of RMT in patients with liver cirrhosis, in the journal Cell Stem Cell. The news comes as Resolution advances its Phase I/II EMERALD trial of its engineered RMT, RTX001, with interim data expected in H2 2026.

Poolbeg Pharma plc announced pre-IND meeting with the FDA for POLB 001

Poolbeg Pharma, a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announced the positive outcome of a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration for POLB 001, the Company’s lead asset, a potential preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome.

Synklino announces treatment of first patient in Phase 1 trial of SYN002 for CMV prevention in kidney transplantation 

Synklino, a clinical-stage biotechnology company developing a first-in-class, ex vivo therapy to transform kidney transplantation outcomes through better CMV prevention, announced the first patient has been dosed in a first-in-human Phase 1 clinical trial of SYN002 for the prevention of cytomegalovirus (CMV) reactivation in kidney transplant recipients.

ViCentra scales commercial manufacturing, triples capacity and strengthens unit economics

ViCentra, a European medical device company commercialising the Kaleido insulin patch pump system, announced that commercial‑scale production of Kaleido consumables, including infusion sets and insulin cartridges, has begun at Phillips Medisize, a Molex company and leading global medical technology contract development and manufacturing organisation (CDMO). The collaboration more than triples Kaleido consumables production capacity, with initial scale to support 17,000+ users. This expanded supply positions ViCentra to add thousands of new users across Germany, the Netherlands and France, with Germany representing the world’s second‑largest insulin pump market.

Hot Topic – Lilly’s Big Investment in Vaccines  

This week’s Hot Topic asks if vaccines are back in fashion after Eli Lilly splashed out almost $4 billion on deals to buy three vaccine companies. Lilly is spending up to $1.5 billion to acquire shingles vaccine developer Curevo – in which VC Medicxi led a $110 million Series B investment round last year – and a similar amount on the Vaccine Company, which has jabs in the pipeline for Epstein-Barr virus, West Nile Virus, dengue fever and Zika. It’s also bought LimmaTech – which Novo Holdings invested in through its REPAIR Impact Fund – for up to $780 million. LimmaTech’s developing vaccines to protect against bacterial pathogens that have a high potential to develop resistant strains, such as S. aureus, thus helping in the vital battle against antimicrobial resistance. Great news for investment in vaccines and infectious diseases!

Watch now!

Optimum attended the third annual J.P. Morgan Oxford Forum 

Optimum’s very own Eleanor Cooper and Joshua Evans attended the third annual J.P. Morgan Oxford Forum for founders and investors, to hear about the latest insights regarding growth-stage funding trends in life sciences and deep tech. 

👥Industry events 

On Helix – Cambridge | 9th Jul 2026 

This July,  One Nucleus presents ON Helix - Disrupting Bio Innovation.  

A one-day conference in Cambridge spotlighting and discussing the breakthrough technologies, policies and business models that are shaping the drug discovery and development landscape. 

An excellent opportunity to connect with the pioneers leading this next wave of disruptive innovation and ensure you stay ahead in a rapidly evolving space. 

Optimum is a proud supporter of One Nucleus events and is happy to share an exclusive 10% F&F discount. Please get in touch if you would like to use this or connect with the team there! 

Optimum’s 18th Annual Healthcare Investor Conference – London | 8th Oct 2026 

Save the date – Thursday the 8th of October 2026! 

The date is set for Optimum’s 18th Annual Healthcare Investor Conference, which returns to the King’s Fund, London this October. 

Join us for a day of invaluable insights from the thought leaders of the life sciences industry! The conference is free but invitation only, so please register your interest to attend here: https://www.optimumcomms.com/irconference2026/  

Follow us on LinkedIn to hear updates on speakers and panellists, as they are announced. 

That’s all folks!  To stay in the know – subscribe to Optimum’s weekly wrap-up today!